Prostate Cancer EMPIRE 2 Findings

Dr. Ashwin Parihar speaks with Dr. Olayinka A. Abiodun-Ojo and Dr. David M. Schuster about findings from the EMPIRE 2 trial, exploring how fluciclovine PET and PSMA PET influence salvage radiotherapy planning for men with recurrent prostate cancer after prostatectomy. The discussion examines the strengths and limitations of each tracer, the importance of prostate bed detection, and where fluciclovine may still have a role in the evolving era of PSMA-targeted imaging. 18F-Fluciclovine or 68Ga-PSMA-11 PET/CT–guided SalvageRadiotherapy Changes in Postprostatectomy BiochemicalRecurrence: Secondary Analysis of the EMPIRE-2 Trial. Abiodun-Ojo and Jani et al. Radiology 2026; 319(3):e251874.